Probe launched into possible safety lapses after cough syrup deaths

Indian authorities are investigating whether safety lapses in the supply of a pharmaceutical solvent may have led to the contamination of a cough syrup that has claimed the lives of at least 24 children in recent months.

According to three health and drug safety officials from Tamil Nadu, a solvent supplied to Sresan Pharmaceutical Manufacturer, the producer of Coldrif cough syrup, is suspected to have been contaminated with a toxic chemical. Officials told Reuters they believe the contamination likely occurred around the time the solvent was provided for the production of a specific batch of the cough syrup.

Preliminary findings suggest that the toxic substance could have entered the manufacturing process through a tainted pharmaceutical ingredient, raising concerns about oversight, quality control, and compliance with safety protocols in the supply chain.

The case has sparked alarm over drug safety regulation and quality control in domestic pharmaceutical manufacturing, prompting calls for stricter enforcement and more rigorous testing of ingredients used in pediatric medications.